Affymetrix (AFFX) Tops Q1 EPS by 6c

Affymetrix (NASDAQ: AFFX) reported Q1 EPS of $0.10, $0.06 better than the analyst estimate of $0.04. Revenue for the quarter came in at $88.7 million versus the consensus estimate of $87.3 million.

“Phase III of our strategic plan is off to a good start. Our priorities are clear, primarily to grow revenues, achieve sustained profitability and build cash to increase our strategic flexibility. In the first quarter, we generated topline growth of 9% on a constant currency basis driven by strong performance of our genotyping and reproductive health businesses,” stated Frank Witney, President and CEO. “We generated an adjusted EBITDA margin of 19% and our earnings per share more than tripled over the prior year.”

For earnings history and earnings-related data on Affymetrix (AFFX) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Eledon Pharmaceuticals, Inc. (ELDN) Misses Q2 EPS by 12c
• Lument Finance Trust (LFT) Misses Q2 EPS by 17c